Clinical Trials in ALS: An Overview

 

 Buy Article Permissions and Reprints

ABSTRACT

Clinical trials in amyotrophic lateral sclerosis (ALS) have been conducted for over half a century now and have incorporated a wide variety of drugs. Most of these trials have had negative results and a cure remains elusive. The explosion in our understanding of molecular biology and parallel developments in clinical epidemiology have opened up a vast number of novel therapeutic strategies. However, advances in statistical analysis, computing, and global communications have also put greater pressure on scientific investigators to improve the design and implementation of clinical trials so that they permit rigorous testing of hypotheses within a solid ethical framework. This article documents the first published trial for all drugs tried clinically in the treatment of ALS, focusing in more detail on the large, multicenter trials of recent years, namely those involving riluzole, ciliary neurotrophic factor, insulin-like growth factor-I, brain-derived neurotrophic factor, and SR57746A. The problems in the design of trials in ALS are discussed, including the selection of end points and surrogate markers of disease progression, and the major parameters in ALS assessment are reviewed.

REFERENCES

• 1 Liversedge L A. Glycocyamine and betaine in motor-neurone disease.  Lancet . 1956;  2 1136-1138
  PubMedGoogle Scholar
• 2 Charcot J M. De la sclérose latérale amyotrophique.  Prog Med . 1874;  2 325, 341-453
  PubMedGoogle Scholar
• 3 Denker P G, Scheinman L. Treatment of amyotrophic lateral sclerosis with vitamin E (alpha-tocopherol).  JAMA . 1941;  116 1893-1895
  PubMedGoogle Scholar
• 4 Fareed G C, Tyler H R. The use of isoprinosine in patients with amyotrophic lateral sclerosis.  Neurology . 1971;  21 937-940
  PubMedGoogle Scholar
• 5 Norris Jr H F, Calanchini P R, Fallat R J, Panchari S, Jewett B. The administration of guanidine in amyotrophic lateral sclerosis.  Neurology . 1974;  24 721-728
  PubMedGoogle Scholar
• 6 Bunina T L, Khondkarian O A, Korshunova T S, Larskii E G, Fuks B B. Treatment of amyotrophic lateral sclerosis with ribonucleotides.  Zh Nevropatol Psikhiatr Im S S Korsakova . 1976;  76 166-174
  PubMedGoogle Scholar
• 7 Olson W H, Simons J A, Halaas G W. Therapeutic trial of tilorone in ALS: lack of benefit in a double-blind, placebo-controlled study.  Neurology . 1978;  28 1293-1295
  PubMedGoogle Scholar
• 8 Norris Jr H F, KS U, Sachais B, Carey M. Trial of baclofen in amyotrophic lateral sclerosis.  Arch Neurol . 1979;  36 715-716
  PubMedGoogle Scholar
• 9 Munsat T L, Easterday C S, Levy S, Wolff S M, Hiatt R. Amantadine and guanidine are ineffective in ALS.  Neurology . 1981;  31 1054-1055
  PubMedGoogle Scholar
• 10 Engel W K, Siddique T, Nicoloff J T. Effect on weakness and spasticity in amyotrophic lateral sclerosis of thyrotropin-releasing hormone.  Lancet . 1983;  2 73-75
  PubMedGoogle Scholar
• 11 Kelemen J, Hedlund W, Orlin J B, Berkman E M, Munsat T L. Plasmapheresis with immunosuppression in amyotrophic lateral sclerosis.  Arch Neurol . 1983;  40 752-753
  PubMedGoogle Scholar
• 12 Bradley W G, Hedlund W, Cooper C. A double-blind controlled trial of bovine brain gangliosides in amyotrophic lateral sclerosis.  Neurology . 1984;  34 1079-1082
  PubMedGoogle Scholar
• 13 Olarte M R, Shafer S Q. Levamisole is ineffective in the treatment of amyotrophic lateral sclerosis.  Neurology . 1985;  35 1063-1066
  PubMedGoogle Scholar
• 14 Norris F H, Denys E H, Fallat R J. Trial of octacosanol in amyotrophic lateral sclerosis.  Neurology . 1986;  36 1263-1264
  PubMedGoogle Scholar
• 15 Mora J S, Munsat T L, Kao K P. Intrathecal administration of natural human interferon alpha in amyotrophic lateral sclerosis.  Neurology . 1986;  36 1137-1140
  PubMedGoogle Scholar
• 16 Brown Jr H R, Hauser S L, Harrington H, Weiner H L. Failure of immunosuppression with a ten- to 14-day course of high-dose intravenous cyclophosphamide to alter the progression of amyotrophic lateral sclerosis.  Arch Neurol . 1986;  43 383-384
  PubMedGoogle Scholar
• 17 Aquilonius S M, Askmark H, Eckernas S A. Cholinesterase inhibitors lack therapeutic effect in amyotrophic lateral sclerosis: a controlled study of physostigmine versus neostigmine.  Acta Neurol Scand . 1986;  73 628-632
  PubMedGoogle Scholar
• 18 Provinciali L, Giovagnoli A R, Di Bella P, Baroni M, Dellantonio R. A therapeutic trial of thymic factor in amyotrophic lateral sclerosis (ALS).  Adv Exp Med Biol . 1987;  209 293-296
  PubMedGoogle Scholar
• 19 Plaitakis A, Smith J, Mandeli J, Yahr M D. Pilot trial of branched-chain amino-acids in amyotrophic lateral sclerosis.  Lancet . 1988;  1 1015-1018
  PubMedGoogle Scholar
• 20 Appel S H, Stewart S S, Appel V. A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis.  Arch Neurol . 1988;  45 381-386
  CrossrefPubMedGoogle Scholar
• 21 Werdelin L, Boysen G, Jensen T S, Mogensen P. Immunosuppressive treatment of patients with amyotrophic lateral sclerosis.  Acta Neurol Scand . 1990;  82 132-134
  PubMedGoogle Scholar
• 22 Szulc-Kuberska J, Klimek A, Stepien H, Woszczak M. Clinical trial of the treatment of amyotrophic lateral sclerosis with bromocriptine.  Neurol Neurochir Pol . 1990;  24 37-41
  PubMedGoogle Scholar
• 23 Askmark H, Aquilonius S M, Gillberg P G. Functional and pharmacokinetic studies of tetrahydroaminoacridine in patients with amyotrophic lateral sclerosis.  Acta Neurol Scand . 1990;  82 253-258
  PubMedGoogle Scholar
• 24 Nevsimal O, Pekarek J, Koubek K, Cech K, Sonkova Z. Low-molecular transfer factor and its use in the treatment of amyotrophic lateral sclerosis.  Cesk Neurol Neurochir . 1991;  54 220-222
  PubMedGoogle Scholar
• 25 Testa D, Caraceni T, Fetoni V, Girotti F. Chronic treatment with L-threonine in amyotrophic lateral sclerosis: a pilot study.  Clin Neurol Neurosurg . 1992;  94 7-9
  PubMedGoogle Scholar
• 26 Majkowski J. Long-term treatment of amyotrophic lateral sclerosis with phthalazinol.  Adv Second Messenger Phosphoprotein Res . 1992;  25 409-416
  PubMedGoogle Scholar
• 27 Westarp M E, Westphal K P, Kolde G. Dermal, serological and CSF changes in amyotrophic lateral sclerosis with and without intrathecal interferon beta treatment.  Int J Clin Pharmacol Ther Toxicol . 1992;  30 81-93
  PubMedGoogle Scholar
• 28 Smith R A, Melmed S, Sherman B. Recombinant growth hormone treatment of amyotrophic lateral sclerosis.  Muscle Nerve . 1993;  16 624-633
  PubMedGoogle Scholar
• 29 Eisen A, Stewart H, Schulzer M, Cameron D. Anti-glutamate therapy in amyotrophic lateral sclerosis: a trial using lamotrigine.  Can J Neurol Sci . 1993;  20 297-301
  PubMedGoogle Scholar
• 30 Drachman D B, Chaudhry V, Cornblath D. Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation.  Ann Neurol . 1994;  35 142-150
  CrossrefPubMedGoogle Scholar
• 31 Mazzini L, Testa D, Balzarini C, Mora G. An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis.  J Neurol . 1994;  241 223-227
  PubMedGoogle Scholar
• 32 Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.  N Engl J Med . 1994;  330 585-591
  CrossrefPubMedGoogle Scholar
• 33 Louwerse E S, Weverling G J, Bossuyt P M, Meyjes F E, de Jong M J. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis.  Arch Neurol . 1995;  52 559-564
  PubMedGoogle Scholar
• 34 Handa I, Matsushita N, Ihashi K. A clinical trial of therapeutic electrical stimulation for amyotrophic lateral sclerosis.  Tohoku J Exp Med . 1995;  175 123-134
  PubMedGoogle Scholar
• 35 Vyth A, Timmer J G, Bossuyt P M, Louwerse E S, de Jong M J. Survival in patients with amyotrophic lateral sclerosis, treated with an array of antioxidants.  J Neurol Sci (suppl). 1996;  139 (99-103)
  PubMedGoogle Scholar
• 36 Miller R G, Smith S A, Murphy J R. A clinical trial of verapamil in amyotrophic lateral sclerosis.  Muscle Nerve . 1996;  19 511-515
  PubMedGoogle Scholar
• 37 Miller R G, Shepherd R, Dao H. Controlled trial of nimodipine in amyotrophic lateral sclerosis.  Neuromuscul Disord . 1996;  6 101-104
  PubMedGoogle Scholar
• 38 Aisen M L, Sevilla D, Edelstein L, Blass J. A double-blind placebo-controlled study of 3,4-diaminopyridine in amyotrophic lateral sclerosis patients on a rehabilitation unit.  J Neurol Sci . 1996;  138 93-96
  CrossrefPubMedGoogle Scholar
• 39 Meucci N, Nobile-Orazio E, Scarlato G. Intravenous immunoglobulin therapy in amyotrophic lateral sclerosis.  J Neurol . 1996;  243 117-120
  CrossrefPubMedGoogle Scholar
• 40 The ALS CNTF Treatment Study Group. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis.  Neurology . 1996;  46 1244-1249
  PubMedGoogle Scholar
• 41 Lange D J, Felice K J, Festoff B W. Recombinant human insulin-like growth factor-I in ALS: description of a double-blind, placebo-controlled study. North American ALS/IGF-I Study Group.  Neurology (suppl 2). 1996;  47 (S93-S94)
  PubMedGoogle Scholar
• 42 Miller R G, Moore D, Young L A. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group.  Neurology . 1996;  47 1383-1388
  PubMedGoogle Scholar
• 43 Cudkowicz M E, Warren L, Francis J W. Intrathecal administration of recombinant human superoxide dismutase 1 in amyotrophic lateral sclerosis: a preliminary safety and pharmacokinetic study.  Neurology . 1997;  49 213-222
  PubMedGoogle Scholar
• 44 Szczudlik A, Tomik B, Slowik A, Kasprzyk K. Assessment of the efficacy of treatment with pimozide in patients with amyotrophic lateral sclerosis: introductory notes.  Neurol Neurochir Pol . 1998;  32 821-829
  PubMedGoogle Scholar
• 45 Kaji R, Kodama M, Imamura A. Effect of ultrahigh-dose methylcoba lamin on compound muscle action potentials in amyotrophic lateral sclerosis: a double-blind controlled study.  Muscle Nerve . 1998;  21 1775-1778
  CrossrefPubMedGoogle Scholar
• 46 Cudkowicz M E, Sexton P M, Ellis T. The pharmacokinetics and pharmacodynamics of Procysteine in amyotrophic lateral sclerosis.  Neurology . 1999;  52 1492-1494
  PubMedGoogle Scholar
• 47 The BDNF Study Group (Phase III). A controlled trial of recombinant methionyl human BDNF in ALS.  Neurology . 1999;  52 1427-1433
  PubMedGoogle Scholar
• 48 Miller R G, Munsat T L, Swash M, Brooks B R. Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology Committee on Research.  J Neurol Sci . 1999;  169 2-12
  CrossrefPubMedGoogle Scholar
• 49 Haverkamp L J, Appel V, Appel S H. Natural history of amyotrophic lateral sclerosis in a database population: validation of a scoring system and a model for survival prediction.  Brain . 1995;  118 707-719
  CrossrefPubMedGoogle Scholar
• 50 Munsat T L. Issues in amyotrophic lateral sclerosis clinical trial design.  Adv Neurol . 1995;  68 209-218
  PubMedGoogle Scholar
• 51 Brooks B R. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial ``Clinical limits of amyotrophic lateral sclerosis'' workshop contributors.  J Neurol Sci (suppl). 1994;  124 (96-107)
  PubMedGoogle Scholar
• 52 Munsat T L. Issues in clinical trial design I: use of natural history controls: a protagonist view.  Neurology . 1996;  47(4 suppl 2) S96-S97
  PubMedGoogle Scholar
• 53 Miller R G, Mitchell J D, Moore D H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).  Cochrane Database Syst Rev . 2000;  2 CD001447
  PubMedGoogle Scholar
• 54 Armon C. How can physicians and their patients with ALS decide to use the newly-available treatments to slow disease progression?.  ALS Other Motor Neuron Disord . 1999;  1 3-14
  PubMedGoogle Scholar
• 55 Mills K R. Motor neuron disease: studies of the corticospinal excitation of single motor neurons by magnetic brain stimulation.  Brain . 1995;  118 971-982
  PubMedGoogle Scholar
• 56 Pioro E P. Proton magnetic resonance spectroscopy (¹H-MRS) in ALS.  ALS Other Motor Neuron Disord (suppl 2). 2000;  1 (S7-S16)
  PubMedGoogle Scholar
• 57 Turner M R, Leigh P N. Positron emission tomography (PET): its potential to provide surrogate markers in ALS.  ALS Other Motor Neuron Disord (suppl 2). 2000;  1 (S17-S22)
  PubMedGoogle Scholar
• 58 Eisen A, Krieger C. ALS therapy, therapeutic trials, and neuroprotection. In: Amyotrophic Lateral Sclerosis: A Synthesis of Research and Clinical Practice Cambridge: Cambridge University Press 1998: 209-237
  Google Scholar
• 59 Fitting J W, Paillex R, Hirt L, Aebischer P, Schluep M. Sniff nasal pressure: a sensitive respiratory test to assess progression of amyotrophic lateral sclerosis.  Ann Neurol . 1999;  46 887-893
  CrossrefPubMedGoogle Scholar
• 60 Andres P L, Hedlund W, Finison L. Quantitative motor assessment in amyotrophic lateral sclerosis.  Neurology . 1986;  36 937-941
  PubMedGoogle Scholar
• 61 Appel V, Stewart S S, Smith G, Appel S H. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience.  Ann Neurol . 1987;  22 328-333
  CrossrefPubMedGoogle Scholar
• 62 The ALS CNTF treatment study (ACTS) phase I-II Study Group. The amyo- trophic lateral sclerosis functional rating scale: assessment of activities of daily living in patients with amyotrophic lateral sclerosis.  Arch Neurol . 1996;  53 141-147
  PubMedGoogle Scholar
• 63 Bergner M, Bobbitt R A, Carter W B, Gilson B S. The Sickness Impact Profile: development and final revision of a health status measure.  Med Care . 1981;  19 787-805
  CrossrefPubMedGoogle Scholar
• 64 McGuire D, Garrison L, Armon C. Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS. SSNJV/CNTF ALS Study Group.  Neurology . 1996;  46 1442-1444
  PubMedGoogle Scholar
• 65 McGuire D, Garrison L, Armon C. A brief quality-of-life measure for ALS clinical trials based on a subset of items from the sickness impact profile. The Syntex-Synergen ALS/CNTF Study Group.  J Neurol Sci (suppl 1) . 1997;  152 (S18-S22)
  PubMedGoogle Scholar
• 66 Jenkinson C, Fitzpatrick R, Brennan C, Bromberg M, Swash M. Development and validation of a short measure of health status for individuals with amyotrophic lateral sclerosis/motor neurone disease: the ALSAQ-40.  J Neurol (suppl 3). 1999;  246 (III16-III21)
  PubMedGoogle Scholar
• 67 Plaitakis A, Caroscio J T. Abnormal glutamate metabolism in amyotrophic lateral sclerosis.  Ann Neurol . 1987;  22 575-579
  CrossrefPubMedGoogle Scholar
• 68 Ince P, Eggett C J, Shaw P J. The role of excitotoxicity in neurological disease.  Rev Contemp Pharmacother . 1997;  8 195-212
  PubMedGoogle Scholar
• 69 Lacomblez L, Bensimon G, Leigh P N, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II.  Lancet . 1996;  347 1425-1431
  CrossrefPubMedGoogle Scholar
• 70 Martinou J C, Martinou I, Kato A C. Cholinergic differentiation factor (CDF/LIF) promotes survival of isolated rat embryonic motoneurons in vitro.  Neuron . 1992;  8 737-744
  CrossrefPubMedGoogle Scholar
• 71 Mitsumoto H, Ikeda K, Klinkosz B. Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNF.  Science . 1994;  265 1107-1110
  PubMedGoogle Scholar
• 72 Miller R G, Bryan W W, Dietz M A. Toxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis.  Neurology . 1996;  47 1329-1331
  PubMedGoogle Scholar
• 73 Stambler N, Charatan M, Cedarbaum J M. Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group.  Neurology . 1998;  50 66-72
  PubMedGoogle Scholar
• 74 Lewis M E, Neff N T, Contreras P C. Insulin-like growth factor-I: potential for treatment of motor neuronal disorders.  Exp Neurol . 1993;  124 73-88
  CrossrefPubMedGoogle Scholar
• 75 Neff N T, Prevette D, Houenou L J. Insulin-like growth factors: putative muscle-derived trophic agents that promote motoneuron survival.  J Neurobiol . 1993;  24 1578-1588
  CrossrefPubMedGoogle Scholar
• 76 Lai E C, Felice K J, Festoff B W. Effect of recombinant human insulin-like growth factor-I on progression of ALS: a placebo-controlled study. The North America ALS/IGF-I Study Group.  Neurology . 1997;  49 1621-1630
  CrossrefPubMedGoogle Scholar
• 77 Borasio G D, Robberecht W, Leigh P N. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group.  Neurology . 1998;  51 583-586
  PubMedGoogle Scholar
• 78 Ackerman S J, Sullivan E M, Beusterien K M. Cost effectiveness of recombinant human insulin-like growth factor I therapy in patients with ALS.  Pharmacoeconomics . 1999;  15 179-195
  PubMedGoogle Scholar
• 79 Henderson C E, Bloch-Gallego E, Camu W. Motoneuron survival factors: biological roles and therapeutic potential.  Neuromuscul Disord . 1993;  3 455-458
  PubMedGoogle Scholar
• 80 Ikeda K, Klinkosz B, Greene T. Effects of brain-derived neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease.  Ann Neurol . 1995;  37 505-511
  CrossrefPubMedGoogle Scholar
• 81 Fournier J, Steinberg R, Gauthier T. Protective effects of SR 57746A in central and peripheral models of neurodegenerative disorders in rodents and primates.  Neuroscience . 1993;  55 629-641
  CrossrefPubMedGoogle Scholar